The truth about fatty liver
The majority of doctors will tell you that there is nothing you can do to reverse fatty liver and that health problems such as cirrhosis and liver failure may be in your future that they will address with the awful “solution” of liver transplant. The truth is the opposite: fatty liver is easily and readily reversible in virtually everybody, provided you take action before irreversible changes take place and are given the right information and tools. In this video, I discuss the three basic phenomena that drive fat deposition, liver damage, and inflammation that lead to this condition: Carbohydrate consumption that drives de novo lipogenesis, the liver’s conversion of sugars to triglycerides Insulin resistance that puts de novo lipogenesis into overdrive Dysbiosis and SIBO that floods the portal circulation draining into the liver with inflammatory compounds (e.g., metabolic endotoxemia) Reverse these conditions, as we do in my programs, and fatty liver easily, quickly, inexpensively becomes a thing of the past with normalization of AST, ALT, GGT blood tests and reversal of fat deposition by ultrasound, MRI, or CT scan. Transcript: let’s talk about this very common condition called fatty liver, in which fat has entered the liver and over time, can do damage to the liver tissue. It’s become incredibly common. About a third of all Americans, about a third of all Americans, now have fatty liver. If you’re overweight, there’s about a 6...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Cheng Han, Yinping Zhang, Marc Redmile-Gordon, Huan Deng, Zhenggui Gu, Qiguo Zhao, Fang Wang
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Peter A. Bain, Adrienne Gregg, Alok K. Pandey, Mohana Krishna Reddy Mudiam, Peta A. Neale, Anu Kumar
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Jinquan Chen, Xuan Li, Wei Jia, Shili Shen, Shengjiong Deng, Bohua Ji, Junjun Chang
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Authors: Bergland OU, Søraas CL, Larstorp ACK, Halvorsen LV, Hjørnholm U, Hoffman P, Høieggen A, Fadl Elmula FEM Abstract PURPOSE: The blood pressure (BP) lowering effect of renal sympathetic denervation (RDN) in treatment-resistant hypertension shows variation amongst the existing randomised studies. The long-term efficacy and safety of RDN require further investigation. For the first time, we report BP changes and safety up to 7 years after RDN, compared to drug adjustment in the randomised Oslo RDN study. MATERIALS AND METHODS: Patients with treatment-resistant hypertension, defined...
Authors: Zhang W, Xu JZ, Lu XH, Li H, Wang D, Wang JG Abstract PURPOSE: We hypothesise that dietary sodium intake interacts with serum uric acid to influence blood pressure (BP) in children and adolescents. In the present study, we investigated ambulatory BP in relation to hyperuricaemia, dietary sodium intake and their interaction in children and adolescents with hypertension. MATERIALS AND METHODS: A total of 616 study participants were 10-24 years old and had primary hypertension diagnosed after admission in a specialised inpatient ward. Ambulatory BP monitoring was performed during hospitalisat...
Conclusion: These findings suggest that consumption of peanuts high in oleic acid (D7) may have the potential to delay primary fatty liver symptoms. PMID: 33033472 [PubMed]
Publication date: Available online 9 October 2020Source: Journal of Genetics and GenomicsAuthor(s): Huiyun Liu, Ke Wang, Huali Tang, Qiang Gong, Lipu Du, Xinwu Pei, Xingguo Ye
More News: Acetylcysteine | Blogging | Brain | Brain Cancers | Cancer | Cancer & Oncology | Carbohydrates | Cardiology | Cirrhosis | Colon Cancer | Colorectal Cancer | Complementary Medicine | CT Scan | Dementia | Diabetes | Diabetes Type 2 | Diets | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Fish | Fish Oil | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Heart | Heart Disease | Heart Transplant | Hepatitis | Herbs | Hypertension | Insulin | Iodine | Liver | Liver Transplant | Magnesium | Neurology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Omega 3 | Organic | Pancreas | Pancreatic Cancer | PET Scan | Probiotics | Sugar | Thyroid | Thyroid Cancer | Transplant Surgery | Transplants | Ultrasound | Urology & Nephrology | Websites | Wheat